Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 1, 2016, Pages 89-97

  Douketis, J D ^a,b   Wang, G ^a   Chan, N ^a,b   Eikelboom, J W ^a,b   Syed, S ^a   Barty, R ^a   Moffat, K A ^a   Spencer, F A ^a,b   Blostein, M ^c   Schulman, S ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Bleeding; Blood coagulation tests; Dabigatran; Direct thrombin inhibitors; Surgery

Indexed keywords

DABIGATRAN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTE THROMBIN TIME; DRUG BLOOD LEVEL; ELECTIVE SURGERY; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPERATIVE BLOOD LOSS; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RISK FACTOR; STANDARDIZATION; THROMBIN TIME; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT INTERRUPTION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; MIDDLE AGED; RISK; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DABIGATRAN; ELECTIVE SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PROSPECTIVE STUDIES; PROTHROMBIN TIME; RISK; THROMBIN TIME; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84955195962     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13178     Document Type: Article

References (42)

1. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120: 2954-62.
2. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118: 1466-74.
3. Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011; 104: 669-76.
4. Lai A, Davidson N, Galloway SW, Thachil J. Perioperative management of patients on new oral anticoagulants. Br J Surg 2014; 101: 742-9.
5. Breuer G, Weiss DR, Ringwald J. New direct oral anticoagulants in the perioperative setting. Curr Opin Anaesthesiol 2014; 27: 409-19.
6. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.): e326S-50S.
7. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, Brown DL, Heit JA, Mulroy MF, Rosenquist RW, Tryba M, Yuan CS. Regional anesthesia in the patient receiving antithrombotic therapy or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition). Reg Anesth Pain Med 2010; 35: 64-101.
8. Gogarten W, Vandermeulen E, van Aken H, Kozek S, Llau JV, Samama CM; European Society of Anesthesiology. Regional anesthesia and antithrombotic agents: recommendations of the European Society of Anesthesiology. Eur J Anesthesiol 2010; 27: 999-1015.
9. Benzon HT, Avram MJ, Green D, Bonow RO. New oral anticoagulants and regional anesthesia. Br J Anesth 2013; 111(S1): i96-113.
10. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-23.
11. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11: 245-52.
12. Castellone DD, van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-7.
13. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
14. Hapgood G, Butler J, Malan E, Chunilal S, Tran H. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110: 308-15.
15. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogné JM, Mullier F. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 283-94.
16. Tripodi A. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. J Thromb Haemost 2013; 11: 576-8.
17. Samama MM. Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay. J Thromb Haemost 2013; 11: 579-80.
18. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283-94.
19. Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013; 11(Suppl. 1): 122-8.
20. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-502.
21. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Söderblom L, Norberg EM, Onelöv L, Rönquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmström RE. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013; 69: 1875-81.
22. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64: 1128-39.
23. Skeppholm M, Hjemdahl P, Antovic JP, Muhrbeck J, Eintrie J, Ronquist-Nii Y, Pohanka A, Beck O, Malmstrom ER. On the monitoring of dabigartan in 'real life' patients with atrial fibrillation. Thromb Res 2014; 134: 783-9.
24. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-8.
25. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem 2013; 59: 807-14.
26. Stang L, Nahirniak S, Butcher K, Szkotak AJ. Dabigatran assessment in patients with acute complications using routine coagulation assays. Blood Coagul Fibrinolysis 2014; 25: 426-34.
27. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-43.
28. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-97.
29. Curvers J, van de Kerkhof D, Stroobants AK, van den Dool E-J, Scharnhorst V. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays. Which assay is helpful? Am J Clin Pathol 2012; 138: 551-8.
30. Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, van der Graaf F, Brunsveld L, van de Kerkhof, D. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatrography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014; 12: 1636-46.
31. Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD. Perioperative management of patients on dabigatran - a prospective cohort study. Circulation 2015; 132: 167-73.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
33. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368: 2084-93.
34. Jamula E, Lloyd NS, Schwalm JD, Airaksinen KE, Douketis JD. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and meta-analysis. Chest 2010; 138: 840-7.
35. Schulman S, Healey JS, Douketis JD, Delaney J, Morillo CA. Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial. Thromb Res 2014; 134: 814-18.
36. ® thrombin inhibitor assay in patients with atrial fibrillation. J Thromb Thrombolysis 2015; 39: 95-100.
37. Lind SE, Boyle ME, Fisher S, Ishimoto J, Trujillo TC, Kiser TH. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol 2014; 141: 665-74.
38. Chin PK, Patterson DM, Zhang M, Jensen BP, Wright DF, Barclay ML, Begg EJ. Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol 2014; 78: 630-8.
39. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-8.
40. Chan NC, Coppens M, Hirsh J, Ginsberg JS, Weitz JI, Vanassche T, Douketis JD, Schulman S, Eikelboom JW. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 2015; 13: 353-9.
41. Eikelboom JW, Weitz JI. Dabigatran monitoring made simple? Thromb Haemost 2013; 110: 393-5.
42. Gosselin R, Hawes E, Moll S, Adcock D. Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels. Am J Clin Pathol 2014; 141: 262-7.